RNTX DEFA14A SEC Filing Analysis

Latest settled — T+5d

RNTX ▼ -0.65% at T+5d

NEUTRAL call ✗ call lost -0.65% · α vs SPY -2.77% · entry $0.9487 → $0.9425

Next anchor: T+20d in 18d

Last close $0.8650 (close Jun 17) · -8.82% from $0.9487 entry

Entry anchored
Jun 5, 03:59 PM ET
via Databento tick

T+1d

-2.98%

call -2.98% · α -2.69%

$0.9204

settled 10d ago

T+5d

-0.65%

call -0.65% · α -2.77%

$0.9425

settled 4d ago

T+20d

—

call — · α —

—

in 18d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Rein Therapeutics filed additional definitive proxy soliciting materials (DEFA14A) for its 2026 Annual Meeting of Stockholders to be held on July 20, 2026. The board recommends voting FOR the election of two Class III directors (Reinhard J. Ambros, Ph.D. and Josef H. von Rickenbach), an increase in authorized shares of common stock, ratification of CBIZ CPAs P.C. as auditor, and an advisory vote on executive compensation. This is a routine notice of meeting and proxy availability with no material financial data.

Actionable Insight

Monitor the upcoming annual meeting for vote outcomes, particularly the authorized share increase which could enable future dilutive financing. Trading impact is minimal as this is a routine procedural filing.

Key Facts

Annual meeting scheduled for July 20, 2026
Board recommends FOR election of two Class III directors: Reinhard J. Ambros, Ph.D. and Josef H. von Rickenbach
Board recommends FOR proposal to increase authorized shares of common stock
Board recommends FOR ratification of CBIZ CPAs P.C. as independent auditor
Board recommends FOR advisory vote on named executive officer compensation
Filing is a routine notice of proxy availability with no financial data disclosed

Financial Impact

No financial figures disclosed in this filing

Risk Factors

Share increase proposal could lead to future dilution if authorized shares are issued
No financial or operational updates provided in this filing

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

75% bullish (8 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

Document	Accession Number
DEFA14A Filing (Primary)	0001193125-26-260812
Document: 0001193125-26-260812-index.html	0001193125-26-260812
Document: 0001193125-26-260812.txt	0001193125-26-260812

8 reports for RNTX

T+1T+5T+20T+60

33% Hit rate 1 of 3 directional calls best @ T+1▲ +0.97%May 1, 2026

Filters

Reports for RNTX — sortable, filterable
	Type				Now
Jun 8, 2026 10d ago	DEFA14A NEUTRAL ★ 3/10	$0.9487 $0.9425	▼ −0.65%	▼ −2.77%	$0.8650 (−8.82%)
May 4, 2026 6w ago	8-K BEARISH ★ 8/10	$1.02 $1.12	▼ −9.80%	▼ −7.82%	$0.8650 (+15.20%)
May 4, 2026 6w ago	424B5 BEARISH ★ 8/10	$1.02 $1.15	▼ −12.75%	▼ −9.81%	$0.8650 (+15.20%)
May 1, 2026 7w ago	Press Release BEARISH ★ 8/10	$1.03 $1.22	▼ −18.45%	▼ −16.10%	$0.8650 (+16.02%)
Apr 29, 2026 7w ago	Press Release NEUTRAL ★ 3/10	$1.28 $1.02	▼ −20.00%	▼ −23.11%	$0.8650 (−32.16%)
Apr 28, 2026 7w ago	S-1 NEUTRAL ★ 5/10	$1.28 $1.02	▼ −20.00%	▼ −23.11%	$0.8650 (−32.16%)
Apr 27, 2026 7w ago	10-K/A NEUTRAL ★ 3/10	$1.49 $1.02	▼ −31.54%	▼ −31.94%	$0.8650 (−41.95%)
Mar 3, 2026 15w ago	Press Release NEUTRAL ★ 5/10	$1.15 $1.25	▲ +8.70%	▲ +9.17%	$0.8650 (−24.78%)

US Market Status

Market Closed — Juneteenth — Opens Mon (76h 14m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access